DK1051179T3 - Anti-estrogen- plus progestin-holdige orale kontraceptiva - Google Patents

Anti-estrogen- plus progestin-holdige orale kontraceptiva

Info

Publication number
DK1051179T3
DK1051179T3 DK98956525T DK98956525T DK1051179T3 DK 1051179 T3 DK1051179 T3 DK 1051179T3 DK 98956525 T DK98956525 T DK 98956525T DK 98956525 T DK98956525 T DK 98956525T DK 1051179 T3 DK1051179 T3 DK 1051179T3
Authority
DK
Denmark
Prior art keywords
oral contraceptives
containing oral
estrogen plus
plus progestin
progestin
Prior art date
Application number
DK98956525T
Other languages
Danish (da)
English (en)
Inventor
Michael Jay Gast
Christopher Paul Miller
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1051179T3 publication Critical patent/DK1051179T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98956525T 1997-11-06 1998-11-04 Anti-estrogen- plus progestin-holdige orale kontraceptiva DK1051179T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96508397A 1997-11-06 1997-11-06
PCT/US1998/023427 WO1999024027A2 (fr) 1997-11-06 1998-11-04 Contraceptifs oraux a base d'anti-oestrogenes associes a un progestatif

Publications (1)

Publication Number Publication Date
DK1051179T3 true DK1051179T3 (da) 2005-10-31

Family

ID=25509417

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98956525T DK1051179T3 (da) 1997-11-06 1998-11-04 Anti-estrogen- plus progestin-holdige orale kontraceptiva

Country Status (28)

Country Link
EP (1) EP1051179B1 (fr)
JP (1) JP2001522798A (fr)
CN (1) CN1278732A (fr)
AR (1) AR016667A1 (fr)
AT (1) ATE304359T1 (fr)
AU (2) AU760540B2 (fr)
BG (1) BG104451A (fr)
BR (1) BR9813982A (fr)
CA (1) CA2307210A1 (fr)
CZ (1) CZ294155B6 (fr)
DE (1) DE69831605T2 (fr)
DK (1) DK1051179T3 (fr)
EA (1) EA200000492A1 (fr)
EE (1) EE04092B1 (fr)
ES (1) ES2246541T3 (fr)
GE (1) GEP20043290B (fr)
HR (1) HRP20000269A2 (fr)
HU (1) HUP0100293A3 (fr)
ID (1) ID24568A (fr)
IL (1) IL135621A0 (fr)
NO (1) NO20002167L (fr)
NZ (1) NZ503890A (fr)
PL (1) PL340623A1 (fr)
SK (1) SK6482000A3 (fr)
TR (1) TR200001268T2 (fr)
UA (1) UA68365C2 (fr)
WO (1) WO1999024027A2 (fr)
ZA (1) ZA9810136B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
HRP20000778B1 (en) * 1998-05-15 2004-10-31 Wyeth Corp 2-phenyl-1-/4-(2-aminoethoxy)-benzyl/-indole in combination with estrogens
EP1212335B1 (fr) * 1999-09-13 2006-01-18 Wyeth Conjugues glucopyranosides de 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
CA2448235A1 (fr) 2001-07-31 2003-02-13 Pfizer Products Inc. Compositions pharmaceutiques, necessaires et methodes faisant intervenir des combinaisons d'agonistes/antagonistes des oestrogenes, d'oestrogenes et de progestines
PT1809602E (pt) 2004-10-27 2008-12-15 Janssen Pharmaceutica Nv Derivados de indole úteis como moduladores do receptor da progesterona
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
ES2935125T3 (es) 2015-12-09 2023-03-01 Univ Illinois Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno
EP3455219A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP4483875A3 (fr) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
WO2018081168A2 (fr) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène
AR110728A1 (es) 2017-01-06 2019-04-24 G1 Therapeutics Inc Terapia combinada para el tratamiento del cáncer
TW201835064A (zh) 2017-02-10 2018-10-01 美商G1治療公司 苯并噻吩雌激素受體調節劑
EP3641762B1 (fr) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. Dégrons et dégronimères à liaison n/o pour la dégradation de protéines
CA3067873A1 (fr) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Formes morphiques de g1t38 et leurs procedes de fabrication
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
CA3144791A1 (fr) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimes d'antagonistes du recepteur des oestrogenes
EP4681715A3 (fr) 2019-12-20 2026-01-28 C4 Therapeutics, Inc. Composés d'isoindolinone et d'indazole pour la dégradation de l'egfr
IL295709A (en) 2020-03-05 2022-10-01 C4 Therapeutics Inc Compounds for targeted degradation of brd9
EP4192458A4 (fr) 2020-08-05 2024-09-04 C4 Therapeutics, Inc. Composés pour la dégradation ciblée de ret
JP2024523839A (ja) 2021-06-08 2024-07-02 シーフォー セラピューティクス， インコーポレイテッド 突然変異体ｂｒａｆを分解する療法薬
KR20250055538A (ko) 2022-08-03 2025-04-24 브리스톨-마이어스 스큅 컴퍼니 Ret 단백질을 조정하기 위한 화합물
JP2025540906A (ja) 2022-11-04 2025-12-17 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔ－ｌｄｄタンパク質阻害剤
CN120569388A (zh) 2022-11-04 2025-08-29 百时美施贵宝公司 Ret-ldd蛋白降解剂
AU2024310341A1 (en) 2023-06-30 2026-02-12 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716118B (en) * 1970-10-05 1972-05-31 Richardson Merrell Inc Contraception
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
ES2162198T3 (es) * 1996-04-19 2001-12-16 American Home Prod Agentes estrogenos.
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive

Also Published As

Publication number Publication date
WO1999024027A3 (fr) 1999-07-15
HUP0100293A2 (hu) 2001-10-28
AR016667A1 (es) 2001-07-25
AU1303199A (en) 1999-05-31
NZ503890A (en) 2002-08-28
PL340623A1 (en) 2001-02-12
TR200001268T2 (tr) 2001-01-22
HUP0100293A3 (en) 2002-12-28
JP2001522798A (ja) 2001-11-20
EE200000211A (et) 2001-04-16
WO1999024027A2 (fr) 1999-05-20
AU2003204896B2 (en) 2006-06-15
ID24568A (id) 2000-07-27
DE69831605D1 (de) 2005-10-20
NO20002167L (no) 2000-06-28
NO20002167D0 (no) 2000-04-27
HRP20000269A2 (en) 2000-12-31
CZ20001661A3 (cs) 2000-12-13
UA68365C2 (en) 2004-08-16
CN1278732A (zh) 2001-01-03
EA200000492A1 (ru) 2000-10-30
ATE304359T1 (de) 2005-09-15
ES2246541T3 (es) 2006-02-16
GEP20043290B (en) 2004-07-26
EP1051179B1 (fr) 2005-09-14
EP1051179A2 (fr) 2000-11-15
AU760540B2 (en) 2003-05-15
BR9813982A (pt) 2000-09-26
DE69831605T2 (de) 2006-06-14
SK6482000A3 (en) 2000-11-07
CZ294155B6 (cs) 2004-10-13
ZA9810136B (en) 2000-05-05
EE04092B1 (et) 2003-08-15
CA2307210A1 (fr) 1999-05-20
IL135621A0 (en) 2001-05-20
BG104451A (en) 2000-12-29

Similar Documents

Publication Publication Date Title
NO20002167D0 (no) Anti-østrogen pluss progestin-inneholdende orale befruktningshindrende midler
ID20233A (id) Komposisi oral
DE59802860D1 (de) Desinfektionsmittel
EP1072253A4 (fr) Compositions a administration orale
DE59506139D1 (de) Orale Retard-Präparation
NO20001612D0 (no) Oralt preparat
MA24473A1 (fr) Formulations
DE59802830D1 (de) Orthesengelenk
EP0836470A4 (fr) Compositions a usage buccal
DE60007530D1 (de) Oral wirksame androgene
DE69827710D1 (de) Kippbecken-WC
ATE218540T1 (de) Mikrobiozide n-sulfonylglycin- alkynyloxyphenethylamid-derivate
ITMI991826A0 (it) Nuova formulazione orale
DE60032510D1 (de) Kondom
DK1334725T3 (da) Östroprogestativt antikonceptionsmiddel
DE69821845D1 (de) Ostomievorrichtung
ID20466A (id) Komposisi oral
ID19885A (id) Tisu lembab
DE69907677D1 (de) Brennstoff-luft-mischgerät
DK0853933T3 (da) Ostomikobling
DE69832127D1 (de) Wässrige Siliconzusammensetzung
ID20328A (id) Toilet
EP0998924A4 (fr) Agents antineoplastiques
DE69804179D1 (de) Photoempfindliche Zusammensetzung
DE59702106D1 (de) Knabber